This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0269881108089602v1 23/5/531    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hewett, K Articles by Modell, J Search for Related Content PubMed PubMed Citation Articles by Hewett, K Articles by Modell, J Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB BUPROPION HYDROCHLORIDE CYCLOHEXANOL VENLAFAXINE HYDROCHLORIDE Social Bookmarking                         What's this?

Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR

¹ GlaxoSmithKline, New Frontier Science Park, Harlow, UK
² Psychiatric Clinic, Academy of Medicine, Choroszcz, Poland
³ Department of Psychiatry, Psychosomatic Institute, Vienna, Austria
⁴ Department of Psychiatry, Klaara-Keskus, Helskinki, Finland
⁵ Department of Psychiatry, Alexander University Hospital, Sofia, Bulgaria
⁶ GlaxoSmithKline, Research Triangle Park, NC, USA
⁷ GlaxoSmithKline, Greenford, UK

^* To whom correspondence should be addressed.

	Abstract

Abstract

The efficacy, safety and tolerability of bupropion XR and venlafaxine XR was assessed and compared with placebo in adult outpatients with major depressive disorder (MDD). Adults meeting DSM-IV criteria for MDD with a minimum Hamilton Depression Rating Scale (HAMD) 17-Item total score of 18 were randomized to eight weeks of double-blind treatment with either bupropion XR (150 mg/day), venlafaxine XR (75 mg/day) or placebo. At the end of the fourth week of treatment, a dosage increase to bupropion XR 300 mg/day or venlafaxine XR 150 mg/day was allowed if, in the opinion of the investigator, response was inadequate. The primary efficacy endpoint was mean change from baseline at week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score last observation carried forward (LOCF). Mean changes from baseline at week 8 (LOCF) in MADRS total score were statistically significant for bupropion XR and venlafaxine XR patients compared to the placebo group: -16.0 for bupropion XR (P = 0.006 vs placebo), -17.1 for venlafaxine XR (P < 0.001 vs placebo) and -13.5 for placebo. Secondary outcomes (including CGI-S, HAM-A, MEI, Q-LES-Q-SF, responder and remitter analyses) also improved significantly for both active treatment groups compared with placebo. The most frequently reported adverse events were dry mouth and insomnia for bupropion XR, and nausea, hyperhidrosis, fatigue, and insomnia for venlafaxine XR. In this double-blind, placebo-controlled trial, bupropion XR at doses up to 300 mg/day and venlafaxine XR at doses up to 150 mg/day demonstrated comparable antidepressant efficacy.

Key Words: bupropion XR, depression, venlafaxine XR

First published on July 17, 2008, doi:10.1177/0269881108089602

Journal of Psychopharmacology 2009;23:531.

A more recent version of this article appeared on July 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?